Clinical trials: Astrocytoma, IDH-Mutant, Grade 4
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)
A Study of 177Lu-PSMA-617 in People With Gliomas
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered
- Trial name
- NCT07223034
- Testing
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma, Astrocytoma, Grade IV
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health…
- Conditions
- Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
- Trial name
- SIGMA (NCT05303519)
- Testing
- safusidenib
- Where
- 61 sites in United States, Australia and 1 more
- Volunteers
- 365 people
- Sponsor
- Nuvation Bio Inc.
Astrocytoma, Grade IV
ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas
This Clinical study is framed in the ALBATROSS Project: Clinically validated decision support system based on pixel level Artificial Intelligent models for deciding treatment in glioblastoma.
- Trial name
- ALBATROSS (NCT05229198)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Juan M Garcia-Gomez
Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in…
- Trial name
- NCT07831369
- Testing
- Valproic Acid (VPA), Irinotecan, Simvastatin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Inova Health Care Services
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to…
- Trial name
- NCT05765812
- Testing
- Debio 0123, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Glioblastoma (GBM), Diffuse Midline Glioma (DMG)
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
- Conditions
- Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Trial name
- NCT06896110
- Testing
- Nivolumab, Azacitidine (AZA), lumbar puncture
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Andrew P. Groves
Astrocytoma, Grade IV, Glioblastoma
BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
The main purposes of this study are: I. To assess that the four habitats within the tumor (HAT and LAT) and edema (IPE and VPE) in high-grade glioma are different at vascular, tissular, cellular and molecular levels. II.
- Conditions
- Astrocytoma, Grade IV, Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype
- Trial name
- BIOhabitats (NCT05375318)
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Juan M Garcia-Gomez
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse…
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma
- Trial name
- NCT07468136
- Testing
- Biospecimen Collection, Eflornithine, Lumbar Puncture
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Glioblastoma, High-grade Glioma
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients.
- Conditions
- Glioblastoma, High-grade Glioma, Glioblastoma, IDH-wildtype, Glioblastoma, IDH-mutant
- Trial name
- SUPRAMAX (NCT06118723)
- Testing
- Supramaximal resection, Maximal safe resection
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 784 people
- Sponsor
- Jasper Gerritsen
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients…
- Trial name
- NCT07544992
- Testing
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques
Rationale: Patients with IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma have a very poor prognosis despite standard treatment consisting of surgery, radiotherapy, and chemotherapy.
- Trial name
- NEXTFRONTIER (NCT06623565)
- Testing
- Multimodal image-guided resection
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement…
- Conditions
- Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, Recurrent Astrocytoma, IDH-Mutant
- Trial name
- NCT06860594
- Testing
- Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 43 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioma (Diagnosis)
GliomaAI-Astro4: MRI-Based Detection of IDH Mutant Astrocytoma Grade 4
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-Astro4 can help detect a specific molecular type of brain tumour called IDH mutant Astrocytoma Grade 4 using routine MRI…
- Conditions
- Glioma, Glioma (Diagnosis), Astrocytoma, Astrocytoma, Grade IV
- Trial name
- GliomaAI-A4 (NCT07673679)
- Testing
- GliomaAI-Astro4
- Where
- India
- Volunteers
- 1,372 people
- Sponsor
- Deep Learning Institute of Radiological Sciences
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a…
- Conditions
- Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma
- Trial name
- NCT07301268
- Testing
- Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden).
- Conditions
- Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
- Trial name
- NCT04145115
- Testing
- Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Where
- 414 sites in United States, Puerto Rico
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
STAR-VACC is a randomized double-blind controlled Phase 2 study assessing clinical efficacy of IDH1-vac in patients with newly diagnosed IDH1-mutant high-grade astrocytomas.
- Trial name
- STAR-VACC (NCT07888647)
- Testing
- IDH1-vac, IS-vac, Temozolomide (TMZ)
- Where
- 13 sites in Germany
- Volunteers
- 216 people
- Sponsor
- German Cancer Research Center
Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4…
- Conditions
- Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
- Trial name
- NCT06815029
- Testing
- Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Anaplastic Astrocytoma, Anaplastic Ependymoma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma
- Trial name
- NCT03434262
- Testing
- Gemcitabine, ribociclib, sonidegib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing…
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV
- Trial name
- NCT05789394
- Testing
- Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection, Craniotomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic